Cognito's $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer's into Parkinsons and beyond.
Expecting pivotal data this year, the company has raised a Series C round to support the launch of a noninvasive device ...
Medical Device Network on MSN
Cognito Therapeutics raises $105M for Alzheimer’s therapeutic advancement
With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s ...
Cognito Therapeutics today announced that it completed the final close of its oversubscribed Series C financing round.
Cognito raised $105 million as it awaits trial data that it hopes will convince the FDA to authorize its Alzheimer’s treatment device.
The startup's medical device consists of headphones and eyewear that deliver sensory stimulation, intended to target contributing factors to Alzheimer’s disease, such as the abnormal electrical ...
Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, presented early-stage cost-effectiveness analysis of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results